Aileron Therapeutics, Inc.

Wyeth

Eric Feyfant

Vincent Guerlavais

Huw M Nash

Carl Elkin

Tomi K Sawyer

Bradford Graves

Jose William Saldanha

Phaik-Eng Sum

Jerauld S Skotnicki

Geertruida Machteld Veldman

Lioudmila Tchistiakova

Tarek Suhayl Mansour

Samuel Goldman

Debra D Donaldson

Kimberly Ann Marquette

Xiang-Yang Tan

Lori J Fitz

Angela Widom

Jason Shaoyun Xiang

Laura Lin

David Brian How

Joshua James Sabatini

Kevin Delos Parris

Marion T Kasaian

Tania Shane

Amy Sze Pui Tam

Nancy L Wood

Steve Yik-Kai Tam

Noriyuki Kawahata

Bradford J Graves

Provided herein are peptidomimetic macrocycles containing amino acid sequences with at least two modified amino acids that form an intramolecular cross-link that can help to stabilize a secondary structure of the amino acid sequence. Suitable sequences for stabilization include those with homology to the p53 protein. These sequences can bind to the MDM2 and/or MDMX proteins. Also provided herein are methods of using such macrocycles for the treatment of diseases and disorders, such as cancers or other disorders characterized by a low level or low activity of a p53 protein or high level of activity of a MDM2 and/or MDMX protein.

Peptidomimetic macrocycles

The present invention provides peptidomimetic macrocycles capable of regulating HIF1&#x3b1; and methods of using such macrocycles for the treatment of diseases.

Peptidomimetic macrocycles and use thereof in regulating HIF1alpha

The disclosed peptidomimetic macrocycles modulate the activity of MCL-1. Myeloid cell leukemia 1 (MCL-1) is a protein that inhibits cell death. Peptidomimetic macrocycles, pharmaceutical compositions, and methods disclosed herein can be used for the treatment of disease in which MCL-1 is over-expressed, such as cancer. In particular, MCL-1-modulating peptidomimetic macrocycles disclosed herein can be applied in the setting of resistance to BCL-2 family inhibitors, which is often engendered by MCL-1 over-expression or hyper-activation.

Peptidomimetic macrocycles as modulators of MCL-1

This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.

Antibodies against human interleukin-13 and uses therefor

The present invention relates to modulators of metalloproteinase activity.

Glutamate aggrecanase inhibitors

Antibodies against human interleukin-13 and pharmaceutical compositions thereof

Growing community of inventors

Lexington, MA, United States of America

Eric Feyfant